刺苞菊甙 | 59952-97-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 刺苞菊甙
• 中文别名: 甲基中氮茚-7-羧酸酯
• 英文名称: carlinoside
• 英文别名: luteolin-6-C-glucosyl-8-C-arabinoside；luteolin-6-C-β-D-glucopyranoside-8-C-α-arabinopyranoside；2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]chromen-4-one
• CAS: 59952-97-5
• 化学式: C₂₆H₂₈O₁₅
• 分子量: 580.499
• InChiKey: XBGYTZHKGMCEGE-VYUBKLCTSA-N

物化性质

• 沸点：
  978.2±65.0 °C(Predicted)
• 密度：
  1.825±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  41
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  267
• 氢给体数：
  11
• 氢受体数：
  15

制备方法与用途

生物活性方面，Carlinoside 是一种具有保肝作用的黄酮类苷类化合物。它能够通过刺激 Nrf2 基因表达，增加胆红素-UGT 活性，从而减少肝脏中胆红素的积累。因此，Carlinoside 对于由肝功能障碍引起的高胆红素血症具有潜在的干预作用。

反应信息

• 作为产物：
  描述：

  木犀草素 、 UDP-arabinose 在 Gentiana crassicaulis flavone 8-C-glycosyltransferase TcCGT₁ 作用下， 以 aq. phosphate buffer 为溶剂， 生成 刺苞菊甙
  参考文献：
  名称：

  Functional Characterization and Protein Engineering of a Glycosyltransferase GcCGT to Produce Flavone 6,8-Di-C- and 6-C-4′-O-Glycosides

  摘要：

  DOI：

  10.1021/acscatal.3c05252

文献信息

• CHALLENGE TEST FOR DIAGNOSING SUBTYPE OF AUTISM SPECTRUM DISEASE
  申请人：Stalicla S.A.

  公开号：EP3479845A1

  公开（公告）日：2019-05-08

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD subtype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to an Nrf2-activator for use in identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the Nrf2-activator is administered to a subject, wherein the subject is a patient previously diagnosed with ASD or a subject displaying clinical signs of ASD and wherein an ASD subtype 1 patient is identified by a negative response.

  本发明涉及一种鉴别自闭症谱系障碍（ASD）亚型1患者的方法，其中该方法包括：向先前诊断为ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示阴性反应，则将该ASD患者鉴别为ASD亚型1患者。同样，本发明涉及一种用于鉴定自闭症谱系障碍（ASD）亚型1患者的Nrf2-激活剂，其中将Nrf2-激活剂施用给受试者，受试者是先前诊断为ASD的患者或显示ASD临床症状的受试者，并且通过阴性反应鉴定ASD亚型1患者。
• BIFUNCTIONAL C-GLYCOSIDE GLYCOSYLTRANSFERASES AND APPLICATION THEREOF
  申请人：CAS Center for Excellence in Molecular Plant Sciences

  公开号：EP4108777A1

  公开（公告）日：2022-12-28

  The present disclosure provides a group of novel uridine diphosphate (UDP)-glycosyltransferases, which are bifunctional C-glycoside arabinosyltransferases and C-glycoside glucosyltransferases. The glycosyltransferases can specifically and efficiently catalyze C-glycoside arabinosylation and glucosylation of dihydrochalcone compounds or 2-hydroxyflavanone compounds, to generate C-glycoside dihydrochalcone or C-glycoside-2-hydroxyflavanone compounds; the C-glycoside-2-hydroxyflavanone compounds are further subjected to a dehydration reaction to form flavone-C-glycoside compounds. The present disclosure also provides an application of the novel UDP-glycosyltransferases to artificially constructed recombinant expression systems to generate C-glycoside dihydrochalcone and flavone-C-glycoside compounds by means of fermentation engineering.

  本公开提供了一组新型二磷酸尿苷（UDP）-糖基转移酶，它们是双功能 C-糖苷阿拉伯糖基转移酶和 C-糖苷葡萄糖基转移酶。糖基转移酶可以特异、高效地催化二氢查尔酮化合物或 2-羟基黄烷酮化合物的 C-糖苷阿拉伯化和葡萄糖基化，生成 C-糖苷二氢查尔酮或 C-糖苷-2-羟基黄烷酮化合物；C-糖苷-2-羟基黄烷酮化合物进一步经脱水反应生成黄酮-C-糖苷化合物。本公开还提供了新型 UDP-糖基转移酶在人工构建的重组表达系统中的应用，通过发酵工程生成 C-糖苷二氢查尔酮和黄酮-C-糖苷化合物。
• Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
  申请人：Auransa Inc.

  公开号：US10806716B2

  公开（公告）日：2020-10-20

  This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

  本公开提供了减少或消除心脏毒性，特别是由癌症治疗或其他疗法引起的心脏毒性的方法和药物组合物。在某些情况下，这些方法和组合物可以预防或减少蒽环类药物治疗引起的心脏毒性。本文提供的方法通常包括在施用抗癌药物或其他疗法的同时施用一种保护剂，如麦角黄素、三黄素、洋槐黄素、黄荆素、槲皮素、二氢洋槐黄素、山柰酚、7,3′,4′,5′-四羟基黄酮和麦角黄素。它们可以包括将保护剂与右雷佐生联合使用。本文提供的组合物包括一种保护剂与另一种保护剂或与一种癌症治疗药物（如蒽环类药物）的共同制剂。
• Composition comprising cannabinoids for relief of pain
  申请人：CANOPY HEALTH INNOVATIONS

  公开号：US11110069B2

  公开（公告）日：2021-09-07

  The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

  本技术一般涉及用于缓解受试者疼痛的包含大麻素的组合物，以及使用此类组合物缓解受试者疼痛的方法。
• Method of identifying ASD phenotype 1 patients
  申请人：Stalicla S.A.

  公开号：US11364311B2

  公开（公告）日：2022-06-21

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.

  本发明涉及一种鉴定自闭症谱系障碍（ASD）表型1患者的方法，其中该方法包括：给先前诊断为特发性ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示出负反应，则将该ASD患者鉴定为ASD表型1患者。同样，本发明还涉及一种对自闭症谱系障碍（ASD）表型1患者进行分类的方法，该方法包括：给受试者施用Nrf2-激活剂，观察受试者在施用Nrf2-激活剂后是否表现出阴性反应，其中受试者是先前诊断为特发性ASD的患者或表现出ASD临床症状的受试者，阴性反应支持将受试者分类为ASD表型1患者。